Serosurvey for Middle East respiratory syndrome coronavirus antibody in dromedary camels and human patients at a secondary care hospital, Illela, Northwest Nigeria

Comp Clin Path. 2022;31(3):537-546. doi: 10.1007/s00580-022-03351-3. Epub 2022 Apr 28.

Abstract

Middle East respiratory syndrome (MERS) is a serious emerging zoonosis. It is characterized by severe infection of the respiratory tract in humans. Dromedary camels are considered to be the most probable origin of the pathogenic Middle East respiratory syndrome coronavirus (MERS-CoV). This cross-sectional survey was carried out to ascertain the seroprevalence of MERS-CoV in dromedary camels at Illela border and human patients in a secondary care hospital in Illela, Sokoto State, Nigeria from November 2016 to January 2017. Serum samples from 74 camels and 39 human patients were collected while a data form was administered to the camel handlers (40) and human patients to obtain information on zoographic characteristics of dromedary camels, demographic characteristics of camel handlers and human patients and some practices of both groups which are likely to predispose to MERS-CoV infection. The serum samples were analyzed for antibodies against MERS-CoV using the indirect Enzyme-Linked Immuno-Sorbent Assay (ELISA). All the camels sampled were seropositive against MERS-CoV and 74% of the human patients had antibodies against MERS. All handlers treated their camels without consulting veterinarians and there was little or no biosecurity measures undertaken. Age, sex, and occupation were not significant determinants for the presence of MERS-CoV antibody in human patients sampled. This study serves as a baseline for similar researches and due to the high seroprevalence obtained in this study for both camels and humans, there is need for trained personnel, surveillance and diagnostic tools at our border posts and animal markets.

Supplementary information: The online version contains supplementary material available at 10.1007/s00580-022-03351-3.

Keywords: Dromedary camels; Humans; MERS-CoV; Secondary care hospital; Seroprevalence.